MedTrace Logo

A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions

NCT02626793 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 391

Last updated 2022-02-08

No results posted yet for this study

Summary

The objective of this NIS is the collection of data on the utilization of Apremilast under routine conditions in Germany. Patients' quality-of-life and treatment satisfaction on treatment with Apremilast in daily practice will be documented. Moreover, physician's and patient's assessments of the effectiveness and safety of Apremilast will be recorded. FPI was 3rd August 2015, LPO was 14th of June 2018. A total of 391 patients have been enrolled.

Conditions

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-03
Primary Completion
2017-06-08
Completion
2018-06-14

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02626793 on ClinicalTrials.gov